TW202045195A - Use of composition containing labisia pumila var. alata extracts in alleviating depression related symptoms - Google Patents
Use of composition containing labisia pumila var. alata extracts in alleviating depression related symptoms Download PDFInfo
- Publication number
- TW202045195A TW202045195A TW108120694A TW108120694A TW202045195A TW 202045195 A TW202045195 A TW 202045195A TW 108120694 A TW108120694 A TW 108120694A TW 108120694 A TW108120694 A TW 108120694A TW 202045195 A TW202045195 A TW 202045195A
- Authority
- TW
- Taiwan
- Prior art keywords
- extract
- item
- patent application
- scope
- kachifatima
- Prior art date
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本發明是有關於含有卡琪花蒂瑪萃取物之組成物在緩解憂鬱症相關症狀之用途。The present invention relates to the use of a composition containing kakifatima extract to relieve symptoms related to depression.
憂鬱症（Depression）是一種普遍的精神疾病，亦是中老年期的常見症狀。憂鬱症患者的典型表現例如是情緒、活動力的明顯改變並且常陷於憂鬱的情感狀態，其對患者的家庭、工作、學習、日常飲食與睡眠都可能會產生負面的影響。目前，有許多藥物，如三環類抗憂鬱劑（tricyclic antidepressants; TCAs），被用於憂鬱症的治療。然而，這類藥物常會誘發各種副作用，例如過度鎮靜（sedation）、情感淡漠（apathy）、疲憊、睡眠障礙、認知障礙以及性慾降低等等。因此，目前仍需要更有效且耐受性更好的抗憂鬱劑。Depression is a common mental illness and a common symptom in middle-aged and elderly people. The typical manifestations of patients with depression are, for example, significant changes in mood and activity, and often falling into a depressed emotional state, which may have a negative impact on the patient's family, work, study, daily diet and sleep. At present, many drugs, such as tricyclic antidepressants (TCAs), are used for the treatment of depression. However, these drugs often induce various side effects, such as excessive sedation, apathy, fatigue, sleep disturbance, cognitive impairment, and decreased libido. Therefore, there is still a need for more effective and better tolerated antidepressants.
卡琪花蒂瑪（植物學名：Labisia pumila var. alata ; 即馬來文的Kacip Fatimah）是一種屬於紫金牛科，生長在東南亞熱帶雨林中常見的植物。民間用法上，卡琪花蒂瑪對於婦女保養方面似有相當的功效；舉例來說，卡琪花蒂瑪可用於做為保健品來幫助更年期婦女達到增強心臟功能、提升記憶力或改善更年期症狀（如熱潮紅、***乾燥、黑斑、情緒不穩定等）等效果。Kacip Fatimah (botanical name: Labisia pumila var. alata ; Kacip Fatimah in Malay) is a plant that belongs to the purple bull family and grows in tropical rain forests in Southeast Asia. In folk usage, Kaqifa Dima seems to be quite effective for women's maintenance; for example, Kaqifa Dima can be used as a health care product to help menopausal women to enhance heart function, improve memory or improve menopausal symptoms ( Such as hot flashes, vaginal dryness, dark spots, emotional instability, etc.).
卡琪花蒂瑪是否具有緩解憂鬱症相關症狀或症候群之功能是值得研究探討的議題。Whether Khaki Fatima has the function of relieving depression-related symptoms or syndromes is an issue worthy of research and discussion.
本發明提供一種卡琪花蒂瑪萃取物的醫療保健用途，特別是，含有卡琪花蒂瑪萃取物之醫藥組成物在製備緩解憂鬱症相關症狀或抗憂鬱症之藥物的用途。經實驗發現，卡琪花蒂瑪萃取物具備緩解憂鬱症相關症狀或抗憂鬱的能力，其有做為緩解憂鬱症相關症狀或抗憂鬱症之醫藥組成物的前景。根據實施例，其中所述醫藥組成物包括卡琪花蒂瑪萃取物做為主要活性成分。The present invention provides a medical and health care use of Kaqifatima extract, in particular, the use of a medicinal composition containing the Kaqifatima extract in the preparation of drugs for relieving depression-related symptoms or anti-depression. Experiments have found that Kaqifatima extract has the ability to relieve depression-related symptoms or anti-depression, and it has the prospect of being a medicinal composition for alleviating depression-related symptoms or anti-depression. According to an embodiment, wherein the pharmaceutical composition includes kachifatima extract as the main active ingredient.
在本發明的一實施例中，所述卡琪花蒂瑪萃取物為藉由用乙醇萃取乾燥的卡琪花蒂瑪植物材料而形成萃取物並乾燥所述萃取物而製得。In an embodiment of the present invention, the kachifatima extract is prepared by extracting dried kachifatima plant materials with ethanol to form an extract and drying the extract.
在本發明的一實施例中，所述卡琪花蒂瑪萃取物為藉由用水萃取乾燥的卡琪花蒂瑪植物材料而形成萃取物並乾燥所述萃取物而製得。In an embodiment of the present invention, the kachifatima extract is prepared by extracting dried kachifatima plant materials with water to form an extract and drying the extract.
在本發明的一實施例中，所述卡琪花蒂瑪植物材料包含卡琪花蒂瑪之葉子。In an embodiment of the present invention, the Kaqi Huatima plant material comprises the leaves of Kaqi Huatima.
在本發明的一實施例中，所述卡琪花蒂瑪萃取物適用的最低有效劑量範圍為50 mg/kg至400mg/kg。In an embodiment of the present invention, the applicable minimum effective dose range of the Kaqifatima extract is 50 mg/kg to 400 mg/kg.
在本發明的一實施例中，所述卡琪花蒂瑪萃取物適用的最低有效劑量範圍為 100mg/kg至300mg/kg。In an embodiment of the present invention, the applicable minimum effective dose range of the Kaqifatima extract is 100 mg/kg to 300 mg/kg.
在本發明的一實施例中，所述組成物為製劑。In an embodiment of the present invention, the composition is a formulation.
在本發明的一實施例中，所述製劑為錠劑、片劑、液劑、粉劑、顆粒劑、散劑、丸劑、滴丸劑、膠囊、軟膏、乳膏、乳膠、凝膠、貼片、注射劑、吸入劑、噴劑或是塞劑。In an embodiment of the present invention, the preparation is a lozenge, tablet, liquid, powder, granule, powder, pill, drop pill, capsule, ointment, cream, latex, gel, patch, injection , Inhalation, spray or suppository.
在本發明的一實施例中，所述組成物為口服製劑。In an embodiment of the present invention, the composition is an oral preparation.
在本發明的一實施例中，所述口服製劑包括錠劑、片劑、液劑、粉劑、顆粒劑、散劑、丸劑、滴丸劑或是膠囊。In an embodiment of the present invention, the oral preparation includes lozenges, tablets, liquids, powders, granules, powders, pills, dropping pills or capsules.
在本發明的一實施例中，所述組成物更包括醫藥上所使用載劑、稀釋劑或賦形劑做為所述組成物中的非活性成分。In an embodiment of the present invention, the composition further includes a pharmaceutical carrier, diluent or excipient as the inactive ingredient in the composition.
在本發明的一實施例中，所述組成物為外用製劑。In an embodiment of the present invention, the composition is an external preparation.
本發明更提供以卡琪花蒂瑪萃取物做為減緩憂鬱症相關症狀之功能性食品的用途。所述功能性食品包括卡琪花蒂瑪萃取物。The present invention further provides the use of kakifatima extract as a functional food for alleviating symptoms related to depression. The functional food includes kakifatima extract.
在本發明的一實施例中，所述功能性食品的形式為液體飲料、膠狀品、膠囊、錠劑、片劑或粉末。In an embodiment of the present invention, the functional food is in the form of a liquid beverage, jelly, capsule, lozenge, tablet or powder.
基於上述，本發明提供一種卡琪花蒂瑪的新用途，其適用於抗憂鬱相關之應用。Based on the above, the present invention provides a new use of Kaqifatima, which is suitable for anti-depression related applications.
為讓本發明的上述特徵和優點能更明顯易懂，下文特舉實施例，並配合所附圖式作詳細說明如下。In order to make the above-mentioned features and advantages of the present invention more comprehensible, the following specific embodiments are described in detail in conjunction with the accompanying drawings.
本發明實施例中所述的卡琪花蒂瑪（Labisia pumila var. alata ）可以包括從卡琪花蒂瑪植物材料中所萃取得到的卡琪花蒂瑪萃取物。植物材料係包括片狀、塊狀、粒狀、或粉末狀之原料。較佳地，為從卡琪花蒂瑪之葉子的植物材料中所萃取得到的卡琪花蒂瑪萃取物，但本發明不以此為限。舉例來說，卡琪花蒂瑪萃取物也可以是從卡琪花蒂瑪之根部或其它部位的植物材料中萃取而得到的。在一些實施例中，所述卡琪花蒂瑪萃取物為藉由用乙醇萃取乾燥的卡琪花蒂瑪植物材料而形成萃取物，並乾燥所述萃取物而製得。在一些實施例中，所述卡琪花蒂瑪萃取物為卡琪花蒂瑪葉的95%乙醇萃取物。在另一些實施例中，所述卡琪花蒂瑪萃取物為藉由用水萃取乾燥的卡琪花蒂瑪植物材料而形成萃取物，並乾燥所述萃取物而製得。然而，本發明不以此為限，且可以包括其它的萃取方式以從卡琪花蒂瑪植物材料萃取出所述卡琪花蒂瑪萃取物。The Labisia pumila var. alata described in the embodiments of the present invention may include a Labisia pumila var. alata extract obtained from a plant material of Labisia pumila . Plant materials include flake, block, granular, or powdered raw materials. Preferably, it is a kachifatima extract obtained from the plant material of the leaves of kachifatima, but the present invention is not limited to this. For example, Kaqifa Tima extract can also be extracted from plant materials from the roots or other parts of Kaqifa Tima. In some embodiments, the kachifatima extract is prepared by extracting dried kachifatima plant materials with ethanol to form an extract, and drying the extract. In some embodiments, the kachifatima extract is a 95% ethanol extract of kachifatima leaves. In other embodiments, the kachifatima extract is prepared by extracting dried kachifatima plant materials with water to form an extract, and drying the extract. However, the present invention is not limited to this, and other extraction methods may be included to extract the Kaqifa Tima plant material from the Kaqifa Tima extract.
另外，本發明實施例中所述的卡琪花蒂瑪萃取物乃涵括其生理學上之功能衍生物，也就是說本發明實施例中所述的卡琪花蒂瑪萃取物包含其於醫藥學上可接受之鹽、其於醫藥學上可接受之固態形式（結晶、半結晶或非晶）、其於醫藥學上可接受之多晶型物、其於醫藥學上可接受之溶劑合物或其醫藥學上可接受之代謝物或醫藥學上可接受之前藥。In addition, the kachifatima extract described in the embodiments of the present invention includes its physiologically functional derivatives, that is to say, the kachifatima extract described in the embodiments of the present invention contains it in Pharmaceutically acceptable salts, their pharmaceutically acceptable solid state forms (crystalline, semi-crystalline or amorphous), their pharmaceutically acceptable polymorphs, their pharmaceutically acceptable solvents The compound or its pharmaceutically acceptable metabolite or pharmaceutically acceptable prodrug.
本發明一些實施例提供使用卡琪花蒂瑪萃取物在製備緩解憂鬱症相關症狀之組成物的用途，所述組成物為含有卡琪花蒂瑪萃取物做為活性成分的醫藥組成物。在一些實施例中，所述組成物包括卡琪花蒂瑪萃取物做為唯一的藥理活性成分。在一些其它實施例中，卡琪花蒂瑪萃取物也可以與其它活性成分一起併用來達到抗憂鬱之效果，本發明不限於此。在一些其它的實施例中，提供一種卡琪花蒂瑪萃取物做為減緩憂鬱症相關症狀之功能性食品的應用。所述功能性食品包括由卡琪花蒂瑪萃取物所組成的活性成分；以及食品上所使用的增味劑、甜味劑、增稠劑或賦形劑做為所述組成物中的非活性成分。Some embodiments of the present invention provide the use of kachifatima extract in preparing a composition for relieving symptoms related to depression. The composition is a pharmaceutical composition containing kachifatima extract as an active ingredient. In some embodiments, the composition includes kachifatima extract as the only pharmacologically active ingredient. In some other embodiments, the kachifatima extract can also be used with other active ingredients to achieve the anti-depressant effect, and the present invention is not limited to this. In some other embodiments, an application of Kaqifatima extract as a functional food for alleviating depression-related symptoms is provided. The functional food includes active ingredients composed of kachifatima extract; and flavor enhancers, sweeteners, thickeners or excipients used in the food as non-volatile ingredients in the composition Active ingredient.
在一些實施例中，當卡琪花蒂瑪萃取物是使用於緩解憂鬱症相關症狀之應用時，其適用劑量為50 mg/kg至400mg/kg。也就是說，其最低有效劑量為約 50mg/kg。在一些實施例中，卡琪花蒂瑪萃取物適用的最低有效劑量範圍為100 mg/kg至300mg/kg。在一些實施例中，卡琪花蒂瑪萃取物適用的最低有效劑量範圍為100 mg/kg至200mg/kg。在一些實施例中，卡琪花蒂瑪萃取物適用的最低有效劑量範圍為150 mg/kg至200mg/kg。當卡琪花蒂瑪萃取物在所述組成物或是功能性食品中的劑量在上述範圍時，其能夠達到減緩憂鬱症相關症狀之效果。In some embodiments, when the Kaqifatima extract is used to relieve symptoms related to depression, the applicable dose is 50 mg/kg to 400 mg/kg. That is, the minimum effective dose is about 50 mg/kg. In some embodiments, the minimum effective dose range for the Kaqifatima extract is 100 mg/kg to 300 mg/kg. In some embodiments, the minimum effective dose range for the kachifatima extract is 100 mg/kg to 200 mg/kg. In some embodiments, the minimum effective dose range for the kachifatima extract is 150 mg/kg to 200 mg/kg. When the dosage of Kaqifatima extract in the composition or functional food is within the above range, it can achieve the effect of alleviating symptoms related to depression.
在一些實施例中，所述組成物為一醫藥組成物或一製劑。在一些實施例中，所述製劑為錠劑、片劑、液劑、粉劑、顆粒劑、散劑、丸劑、滴丸劑、膠囊、軟膏、乳膏、乳膠、凝膠、貼片、注射劑、吸入劑、噴劑或是塞劑。在一些實施例中，所述製劑可以為口服製劑，但本發明並不以此為限制。所述口服製劑是指以口服形式施用或可適合於經口投與。出於本發明之目的，口服製劑形式包含膠囊、錠劑、丸劑、顆粒劑、散劑、滴劑及滴丸劑。舉例而言，其製劑可為經包覆或未經包覆、起泡、可溶、口內崩散、腸溶或緩釋錠劑；糖衣錠劑；硬膠囊；軟膠囊；顆粒形式；丸劑；片劑形式調配組成物。較佳地，口服製劑形式為錠劑或膠囊。In some embodiments, the composition is a pharmaceutical composition or a preparation. In some embodiments, the formulation is a lozenge, tablet, liquid, powder, granule, powder, pill, drop pill, capsule, ointment, cream, latex, gel, patch, injection, inhalation , Spray or suppository. In some embodiments, the formulation may be an oral formulation, but the present invention is not limited thereto. The oral formulation refers to administration in an oral form or may be suitable for oral administration. For the purpose of the present invention, oral preparation forms include capsules, lozenges, pills, granules, powders, drops, and pills. For example, the preparation may be coated or uncoated, foamed, soluble, orally disintegrating, enteric-coated or sustained-release tablets; sugar-coated tablets; hard capsules; soft capsules; granular forms; pills; The composition is formulated in tablet form. Preferably, the oral preparation is in the form of tablets or capsules.
在一些實施例中，所述組成物為健康食品組成物、功能性食品組成物、機能保健食品組成物，甚或是可用於作為預防生理機能改變的食品組成物或搭配改變外表機能的食品組成物等等，但並不以此為限制。在一些實施例中，所述食品組成物更包括添加劑、載劑、稀釋劑或賦形劑做為所述組成物中的其他非活性成分。所述載劑、稀釋劑或賦形劑並無特別限制，且可以配合不同的組合物型態或劑型來進行調整。舉例來說，添加劑和賦形劑包括但不限於防黏劑、防發泡劑、緩衝劑、聚合物、抗氧化劑、防腐劑、螯合劑、黏性調節劑、張力調節劑、調味劑、著色劑、香味劑、遮光劑、懸浮劑、黏合劑、填充劑、塑化劑、潤滑劑及其混合物。在一些實施例中，所述組成物更包括食品上所使用的增味劑、甜味劑、增稠劑或賦形劑做為所述組成物中的非活性成分。In some embodiments, the composition is a health food composition, a functional food composition, a functional health food composition, or even a food composition that can be used as a food composition that prevents changes in physiological functions or a food composition that changes appearance functions Wait, but not as a limit. In some embodiments, the food composition further includes additives, carriers, diluents or excipients as other inactive ingredients in the composition. The carrier, diluent or excipient is not particularly limited, and can be adjusted according to different composition forms or dosage forms. For example, additives and excipients include, but are not limited to, anti-sticking agents, anti-foaming agents, buffers, polymers, antioxidants, preservatives, chelating agents, viscosity regulators, tonicity regulators, flavoring agents, coloring Agents, fragrances, sunscreens, suspending agents, binders, fillers, plasticizers, lubricants and mixtures thereof. In some embodiments, the composition further includes flavor enhancers, sweeteners, thickeners or excipients used in foods as inactive ingredients in the composition.
在一些實施例中，作為減緩憂鬱症相關症狀之功能性食品，可以使用由卡琪花蒂瑪萃取物所組成的組合物或包含卡琪花蒂瑪萃取物的組合物作為主要活性成分。在一些實施例中，所述功能性食品可呈現為液體飲料、膠狀品、膠囊、錠劑、片劑或粉末形式，但並不以此為限制。舉例來說，所述功能性食品可以是任何可藉由口服形式服用或食用的功能性食品。In some embodiments, as a functional food for alleviating depression-related symptoms, a composition composed of kachifatima extract or a composition containing kachifatima extract may be used as the main active ingredient. In some embodiments, the functional food may be in the form of a liquid beverage, gel, capsule, lozenge, tablet or powder, but it is not limited thereto. For example, the functional food may be any functional food that can be taken or eaten in oral form.
針對本發明實施例中的卡琪花蒂瑪萃取物的應用與功效，將以下列實施例來做為舉例說明。然而，下列的實施例僅是輔助說明，而並非用以限定本發明。實施例 Regarding the application and efficacy of the kachifatima extract in the embodiments of the present invention, the following embodiments will be used as examples. However, the following embodiments are only an auxiliary description, and are not intended to limit the present invention. Example
在本實施例中，將測試各種劑量之卡琪花蒂瑪萃取物對於小鼠在尾部懸吊試驗（tail suspension test；TST）中帶來的影響。In this example, the effects of various doses of Kaqifatima extract on mice in a tail suspension test (TST) will be tested.
本發明實施例中使用的雌性ICR小鼠（4週）是購買自台灣BioLASCO Co., Ltd。小鼠餵養於大葉大學之動物中心，溫度調控於22 ± 2℃，相對濕度55 ± 5%，且於實驗前一周施予12小時光照/12小時黑暗週期。小鼠是提供其一般可選擇的動物飼料以及飲用水。所有研究均按照美國國立衛生研究院（National Institutes of Health；NIH）實驗動物護理和使用指南進行。所有測試均在國際疼痛研究協會的指導下進行。另外，實驗方案經大葉大學動物研究委員會批准。尾部懸吊試驗 The female ICR mice (4 weeks) used in the examples of the present invention were purchased from Taiwan BioLASCO Co., Ltd. The mice were fed in the Animal Center of Daye University, the temperature was regulated at 22 ± 2℃, the relative humidity was 55 ± 5%, and they were given a 12-hour light/12-hour dark cycle one week before the experiment. Mice are provided with their usual choice of animal feed and drinking water. All studies were conducted in accordance with the National Institutes of Health (National Institutes of Health; NIH) laboratory animal care and use guidelines. All tests were performed under the guidance of the International Association for the Study of Pain. In addition, the experimental protocol was approved by the Animal Research Committee of Daye University. Tail suspension test
一般來說，動物無法用語言表達其憂鬱或負面的情緒，睡眠障礙或食慾減退也很難與身體疾病的因素分辨，只能做為憂鬱症的佐證指標。因此，做為憂鬱症的症狀類比模式，一般是觀察動物是否有自發性活動來確認其有無活動遲緩的問題，或是，小鼠在無助的症狀下，可以從小鼠放棄逃避對其生命有威脅的電擊、放棄在水中或被懸吊在半空中時的掙扎來加以評估。Generally speaking, animals cannot express their depression or negative emotions with words. Sleep disturbance or loss of appetite is also difficult to distinguish from the factors of physical diseases, and can only be used as a supporting indicator of depression. Therefore, as a symptom analogy model of depression, it is generally to observe whether the animal has spontaneous activity to confirm whether it has the problem of slow activity, or when the mouse is helpless, it can give up and escape from the mouse. The threat of electric shock, the struggle when giving up in the water or being suspended in mid-air are evaluated.
尾部懸吊試驗（tail suspension test；TST）即為一種廣泛被用來做篩選抗憂鬱劑的藥理學測驗的症狀類比模式。在尾部懸吊試驗中，當小鼠的尾巴被吊起而使整個身軀懸在半空中時，其會為了掙脫而掙扎扭動，但是幾分鐘之後，小鼠就會變得無助而不再掙扎扭動。通常，小鼠靜止不動的時間越長表示小鼠越容易無助/絕望。目前，已經有許多的研究證明小鼠靜止不動的時間可以因為給與抗憂鬱劑而縮短。The tail suspension test (TST) is a symptom analogy model that is widely used as a pharmacological test for screening antidepressants. In the tail suspension test, when the mouse's tail is suspended and the whole body is suspended in the air, it will struggle to break free and twist, but after a few minutes, the mouse will become helpless and no longer Struggling to twist. Generally, the longer the mouse stays still, the more likely it is to be helpless/desperate. At present, there have been many studies that prove that the time that mice stay still can be shortened by the administration of antidepressants.
在本發明實施例中，是將小鼠分為六組，其分別包括控制組（CON：0.9%的食鹽水）、抗憂鬱劑組（IMI：20mg/kg的三環抗憂鬱劑伊米帕明(Imipramine)）、卡琪花蒂瑪萃取物37.5mg/kg劑量組（KF37.5）、卡琪花蒂瑪萃取物75mg/kg劑量組（KF75）、卡琪花蒂瑪萃取物150mg/kg劑量組（KF150）以及卡琪花蒂瑪萃取物300mg/kg劑量組（KF300）。上述的卡琪花蒂瑪萃取物皆為運用乙醇萃取乾燥的卡琪花蒂瑪之葉子而形成萃取物並乾燥所述萃取物而製得。所萃取出的卡琪花蒂瑪萃取物是經Tween 20溶解後調整成0.5%甲基纖維素（CMC）溶液。單劑測試 （ Single dose test ） In the embodiment of the present invention, the mice are divided into six groups, which respectively include a control group (CON: 0.9% saline) and an antidepressant group (IMI: 20 mg/kg of the tricyclic antidepressant imipa Ming (Imipramine), Kaqifatima extract 37.5mg/kg dose group (KF37.5), Kaqifatima extract 75mg/kg dose group (KF75), Kaqifatima extract 150mg/ The kg dose group (KF150) and the 300mg/kg dose group of Kaqifatima extract (KF300). The above-mentioned kachifatima extracts are all prepared by extracting dried kachifatima leaves with ethanol to form an extract and drying the extract. The extracted kakifatima extract is dissolved in Tween 20 and adjusted to a 0.5% methylcellulose (CMC) solution. Single dose test (Single dose test)
在尾部懸吊試驗開始60分鐘之前，是分別給予小鼠單劑且不同劑量的卡琪花蒂瑪萃取物（37.5mg/kg、75mg/kg、150mg/kg、300mg/kg）以及單劑的三環抗憂鬱劑（IMI：20mg/kg）。在尾部懸吊試驗中，是將各小鼠隔離，並將其尾部約1公分運用膠帶固定將其懸掛在離地面50公分處。接著，在6分鐘的時間內，測量小鼠保持不動的時間（即無掙扎時間）。只有當小鼠被動地懸掛，並且保持完全不動時，才會認定小鼠是無掙扎的。實驗結果如圖1所示。60 minutes before the start of the tail suspension test, mice were given a single dose of Kaqifatima extract (37.5mg/kg, 75mg/kg, 150mg/kg, 300mg/kg) and a single dose. Tricyclic antidepressant (IMI: 20mg/kg). In the tail suspension test, each mouse was isolated, and the tail was about 1 cm fixed with tape and suspended 50 cm from the ground. Then, in 6 minutes, measure the time that the mouse stays still (i.e. time without struggle). Only when the mouse hangs passively and remains completely motionless, will the mouse be deemed to be free of struggle. The experimental results are shown in Figure 1.
圖1為使用單劑卡琪花蒂瑪萃取物對於尾部懸吊試驗中的小鼠無掙扎時間的試驗結果。在圖1中，各數值以平均值±SEM（平均標準誤差）來表示，其中**P＜0.01是相較於控制組（CON：0.9%的食鹽水）。如圖1的實驗結果所示，三環抗憂鬱劑（IMI：20mg/kg）能夠明顯地降低小鼠的無掙扎時間，證明其抗憂鬱的效果。另外，在使用低劑量的卡琪花蒂瑪萃取物（37.5mg/kg、75mg/kg、150mg/kg）時，雖然小鼠的無掙扎時間有略微降低，但其效果並不是很明顯。在使用高劑量的卡琪花蒂瑪萃取物（300mg/kg）時，其能夠明顯地降低小鼠的無掙扎時間，顯示其緩解憂鬱症相關症狀之效果。經由上述實驗，可以得知的是，使用單劑且高劑量的卡琪花蒂瑪萃取物時，其能夠達到與三環抗憂鬱劑（IMI：20mg/kg）類似的抗憂鬱效果。七天重複劑量 測試（ Repeated dose test ） Figure 1 shows the results of a single dose of Kaqifatima extract on mice in the tail suspension test without struggling time. In Figure 1, each value is represented by the mean ± SEM (mean standard error), where **P<0.01 is compared to the control group (CON: 0.9% saline). As shown in the experimental results in Figure 1, the tricyclic antidepressant (IMI: 20mg/kg) can significantly reduce the struggle-free time of mice, proving its antidepressant effect. In addition, when using low-dose Kaqifatima extract (37.5mg/kg, 75mg/kg, 150mg/kg), although the mice's struggle-free time was slightly reduced, the effect was not very obvious. When using a high dose of Kaqifatima extract (300mg/kg), it can significantly reduce the struggle-free time of mice, showing its effect on alleviating symptoms related to depression. Through the above experiments, it can be known that when a single and high dose of Kaqifatima extract is used, it can achieve antidepressant effects similar to tricyclic antidepressants (IMI: 20mg/kg). Seven days repeated dose tested (Repeated dose test)
在尾部懸吊試驗開始之前，是連續七天分別重複給予小鼠不同劑量的卡琪花蒂瑪萃取物（37.5mg/kg、75mg/kg、150mg/kg、300mg/kg）以及三環抗憂鬱劑（IMI：20mg/kg）。尾部懸吊試驗的試驗方式與前述相同，因此不再贅述。尾部懸吊試驗的實驗結果如圖2所示。Before the start of the tail suspension test, mice were repeatedly given different doses of Kaqifatima extract (37.5mg/kg, 75mg/kg, 150mg/kg, 300mg/kg) and tricyclic antidepressants for seven consecutive days. (IMI: 20mg/kg). The test method of the tail suspension test is the same as the above, so it will not be repeated. The experimental results of the tail suspension test are shown in Figure 2.
圖2 為給予七天重複劑量的卡琪花蒂瑪萃取物或抗憂鬱劑對於尾部懸吊試驗中的小鼠無掙扎時間的試驗結果。在圖2中，各數值以平均值±SEM（平均標準誤差）來表示，其中**P＜0.01是相較於控制組（CON：0.9%的食鹽水）。如圖2的實驗結果所示，在連續七天重複給予三環抗憂鬱劑（IMI：20mg/kg）後，其能夠明顯地降低小鼠的無掙扎時間，證明其抗憂鬱的效果。另外，在連續七天重複給予低劑量的卡琪花蒂瑪萃取物（37.5mg/kg、75mg/kg、150mg/kg）時，小鼠的無掙扎時間有越來越低的傾向。在使用高劑量的卡琪花蒂瑪萃取物（300mg/kg）時，其能夠明顯地降低小鼠的無掙扎時間，顯示其緩解憂鬱症相關症狀的效果。經由上述實驗，可以得知的是，若是重複給予卡琪花蒂瑪萃取物時，其抗憂鬱效果會較為明顯。十四天重複劑量 測試（ Repeated dose test ） Figure 2 shows the test results of no struggling time for mice in the tail suspension test given by repeated doses of Kaqifatima extract or antidepressant for seven days. In Figure 2, each value is represented by the mean±SEM (mean standard error), where **P<0.01 is compared to the control group (CON: 0.9% saline). As shown in the experimental results in Figure 2, after repeated administration of tricyclic antidepressants (IMI: 20 mg/kg) for seven consecutive days, it can significantly reduce the struggle-free time of mice, proving its antidepressant effect. In addition, when repeated administration of low-dose Kaqifatima extract (37.5mg/kg, 75mg/kg, 150mg/kg) for seven consecutive days, the mice's struggle-free time tended to decrease. When using a high dose of Kaqifatima extract (300mg/kg), it can significantly reduce the struggle-free time of mice, showing its effect on alleviating symptoms related to depression. Through the above experiments, it can be known that the anti-depressant effect will be more obvious when Kaqifatima extract is repeatedly administered. Fourteen days repeated dose test ( Repeated dose test )
在尾部懸吊試驗開始之前，是連續十四天分別重複給予小鼠不同劑量的卡琪花蒂瑪萃取物（37.5mg/kg、75mg/kg、150mg/kg、300mg/kg）以及三環抗憂鬱劑（IMI：20mg/kg）。尾部懸吊試驗的試驗方式與前述相同，因此不再贅述。尾部懸吊試驗的實驗結果如圖3所示。Before the start of the tail suspension test, mice were repeatedly given different doses of Kaqifatima extract (37.5mg/kg, 75mg/kg, 150mg/kg, 300mg/kg) and tricyclic antibodies for 14 consecutive days. Depressants (IMI: 20mg/kg). The test method of the tail suspension test is the same as the above, so it will not be repeated. The experimental results of the tail suspension test are shown in Figure 3.
圖3為給予十四天重複劑量的卡琪花蒂瑪萃取物或抗憂鬱劑對於尾部懸吊試驗中的小鼠無掙扎時間的試驗結果。各數值以平均值±SEM（平均標準誤差）來表示，其中*P＜0.05，**P＜0.01是相較於控制組（CON：0.9%的食鹽水）。如圖3的實驗結果所示，在連續十四天重複給予三環抗憂鬱劑（IMI：20mg/kg）後，其能夠明顯地降低小鼠的無掙扎時間，證明其抗憂鬱的效果。另外，在連續十四天重複給予卡琪花蒂瑪萃取物時，150mg/kg劑量以及300mg/kg劑量的卡琪花蒂瑪萃取物皆能明顯地降低小鼠的無掙扎時間，顯示其緩解憂鬱症相關症狀的效果。經由上述實驗，可以得知的是，若是重複給予卡琪花蒂瑪萃取物時，卡琪花蒂瑪萃取物的適用劑量可以降低至150mg/kg。以線性外推法預測其可能可以適用的最低有效劑量可介於100mg/kg至300mg/kg的範圍之間。Figure 3 shows the test results of no struggling time of mice in the tail suspension test given to the repeated doses of Kaqifatima extract or antidepressant for 14 days. The values are expressed as mean±SEM (mean standard error), where *P<0.05 and **P<0.01 are compared to the control group (CON: 0.9% saline). As shown in the experimental results of Figure 3, after repeated administration of tricyclic antidepressants (IMI: 20 mg/kg) for 14 consecutive days, it can significantly reduce the struggle-free time of mice, proving its antidepressant effect. In addition, when Kaqifatima extract was administered repeatedly for 14 consecutive days, both 150mg/kg and 300mg/kg of Kaqifatima extract could significantly reduce the struggling-free time of mice, showing its relief The effect of depression-related symptoms. Through the above experiments, it can be known that if the Kaqifatima extract is repeatedly administered, the applicable dose of Kaqifatima extract can be reduced to 150mg/kg. The lowest effective dose predicted by linear extrapolation may be within the range of 100 mg/kg to 300 mg/kg.
綜上所述，本發明的實驗結果發現，卡琪花蒂瑪萃取物能夠帶來與三環抗憂鬱劑類似的抗憂鬱效果。若是服用單劑卡琪花蒂瑪萃取物時，則可能需要使用較高劑量的卡琪花蒂瑪萃取物。然而，若是增加卡琪花蒂瑪萃取物的服用期間時，即使是低劑量的卡琪花蒂瑪萃取物也能夠達到抗憂鬱效果。基於此，卡琪花蒂瑪萃取物具備緩解憂鬱症相關症狀的能力，其有做為抗憂鬱之組成物或是功能性食品的前景。In summary, the experimental results of the present invention have found that Kaqifatima extract can bring antidepressant effects similar to tricyclic antidepressants. If you take a single dose of Kaqifatima extract, you may need to use a higher dose of Kaqifatima extract. However, if the period of taking Kaqifatima extract is increased, even a low dose of Kaqifatima extract can achieve antidepressant effects. Based on this, Kaqifatima extract has the ability to relieve symptoms related to depression, and it has the prospect of being an antidepressant composition or a functional food.
雖然本發明已以實施例揭露如上，然其並非用以限定本發明，任何所屬技術領域中具有通常知識者，在不脫離本發明的精神和範圍內，當可作些許的更動與潤飾，故本發明的保護範圍當視後附的申請專利範圍所界定者為準。Although the present invention has been disclosed in the above embodiments, it is not intended to limit the present invention. Anyone with ordinary knowledge in the technical field can make some changes and modifications without departing from the spirit and scope of the present invention. The scope of protection of the present invention shall be determined by the scope of the attached patent application.
CON:控制組 IMI:抗憂鬱劑組 KF37.5:卡琪花蒂瑪萃取物37.5mg/kg劑量組 KF75:卡琪花蒂瑪萃取物75mg/kg劑量組 KF150:卡琪花蒂瑪萃取物150mg/kg劑量組 KF300:卡琪花蒂瑪萃取物300mg/kg劑量組CON: control group IMI: antidepressant group KF37.5: Kaqi Fatima extract 37.5mg/kg dose group KF75: 75mg/kg dose group of Kaqifatima extract KF150: 150mg/kg dose group of Kaqifatima extract KF300: Kaqifatima extract 300mg/kg dose group
圖1為使用單劑卡琪花蒂瑪萃取物或抗憂鬱劑對於尾部懸吊試驗中的小鼠無掙扎時間的試驗結果。 圖2 為給予七天重複劑量的卡琪花蒂瑪萃取物或抗憂鬱劑對於尾部懸吊試驗中的小鼠無掙扎時間的試驗結果。 圖3為給予十四天重複劑量的卡琪花蒂瑪萃取物或抗憂鬱劑對於尾部懸吊試驗中的小鼠無掙扎時間的試驗結果。Figure 1 shows the results of a single dose of Kaqifatima extract or an antidepressant on mice in the tail suspension test without struggling time. Figure 2 shows the test results of no struggling time of mice in the tail suspension test given to repeated doses of Kaqifatima extract or antidepressant for seven days. Figure 3 shows the test results of no struggling time of mice in the tail suspension test given to the repeated doses of Kaqifatima extract or antidepressant for 14 days.
CON:控制組 CON: control group
IMI:抗憂鬱劑組 IMI: antidepressant group
KF37.5:卡琪花蒂瑪萃取物37.5mg/kg劑量組 KF37.5: Kaqi Fatima extract 37.5mg/kg dose group
KF75:卡琪花蒂瑪萃取物75mg/kg劑量組 KF75: 75mg/kg dose group of Kaqifatima extract
KF150:卡琪花蒂瑪萃取物150mg/kg劑量組 KF150: 150mg/kg dose group of Kaqifatima extract
KF300:卡琪花蒂瑪萃取物300mg/kg劑量組 KF300: Kaqifatima extract 300mg/kg dose group
Claims (14)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW108120694A TWI720511B (en) | 2019-06-14 | 2019-06-14 | Use of composition containing labisia pumila var. alata extracts in alleviating depression related symptoms |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW108120694A TWI720511B (en) | 2019-06-14 | 2019-06-14 | Use of composition containing labisia pumila var. alata extracts in alleviating depression related symptoms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202045195A true TW202045195A (en) | 2020-12-16 |
| TWI720511B TWI720511B (en) | 2021-03-01 |
Family
ID=74668255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW108120694A TWI720511B (en) | 2019-06-14 | 2019-06-14 | Use of composition containing labisia pumila var. alata extracts in alleviating depression related symptoms |
Country Status (1)
| Country | Link |
|---|---|
| TW (1) | TWI720511B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024096818A1 (en) * | 2022-10-31 | 2024-05-10 | Delightex Pte. Ltd. | Compositions and methods for enhancing mental wellbeing |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3053784B1 (en) * | 2016-07-07 | 2020-01-17 | Airbus Defence And Space Sas | METHODS FOR DETERMINING AND CONTROLLING THE TEMPERATURE OF AN ELECTRIC PROPELLER |
| CN107574102A (en) * | 2017-10-30 | 2018-01-12 | 黑龙江省科学院大庆分院 | A kind of wild Cranberry health liquor that can activate women function and preparation method thereof |
-
2019
- 2019-06-14 TW TW108120694A patent/TWI720511B/en active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024096818A1 (en) * | 2022-10-31 | 2024-05-10 | Delightex Pte. Ltd. | Compositions and methods for enhancing mental wellbeing |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI720511B (en) | 2021-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0988028B1 (en) | Use of a composition comprising capsaicin or resiniferatoxin for the treatment of Irritable Bowel Syndrome | |
| JP6343389B2 (en) | Use of a fililine / filigenin composition in the preparation of a drug or health care product for the reduction and / or treatment of viral diseases, and a drug or health care product for the treatment of viral diseases | |
| JP2008542300A (en) | Compositions and methods for preventing and treating conditions associated with inflammation | |
| WO2010133015A1 (en) | Pharmaceutical composition for treating depression and preparative method and use thereof | |
| WO2021179950A1 (en) | Use of pharmaceutical composition in preparing anti-viral drug | |
| CN106573029B (en) | Composition of valerian root extract and lavender oil for the treatment of sleep disorders | |
| WO2021232836A1 (en) | Cannabinoid compounds and application thereof in treatment of parkinson's disease | |
| TWI720511B (en) | Use of composition containing labisia pumila var. alata extracts in alleviating depression related symptoms | |
| JP6369931B2 (en) | Anti-obesity agent | |
| WO2019011350A1 (en) | Fenlean (flz) crystal g form, preparation method, and composition and use thereof | |
| JP4863875B2 (en) | Treatment for depression comprising prickly pear plant parts and / or extracts therefrom | |
| CN107382954A (en) | Wild anistree neolignan and preparation method thereof, application and pharmaceutical composition | |
| JP7335954B2 (en) | Use of bald head saponin B4 in medicine for anti-acute gouty arthritis | |
| TW201106959A (en) | Composition for preventing or treating irritable bowel syndrome | |
| WO2016124080A1 (en) | Use of 20(r)-ginsenoside rg3 in preparation of drug for preventing or/and treating obesity and drug | |
| JP6407545B2 (en) | Pharmaceutical composition | |
| KR101987418B1 (en) | A composition comprising herbal mixture extract for neuroprotection | |
| TW201620507A (en) | Oral composition | |
| CN106822152B (en) | Pharmaceutical composition and application thereof | |
| KR100965305B1 (en) | Composition for preventing or treating a disease mediated by overexpression of heat shock protein 27 | |
| CN107582866B (en) | Application method of dendrobium officinale and amlodipine in preparation of medicine for treating hypertension | |
| CN111329852A (en) | Application of 4-phenylbutyrate derivative in preparation of medicine for treating cerebral ischemia-reperfusion injury | |
| CN112691102A (en) | Application of baicalein in preventing and treating Parkinson's disease/Parkinson's syndrome depression symptoms | |
| TWI717757B (en) | Use of composition containing labisia pumila var. alata extracts in improving acute hemorrhagic anemia | |
| CN111212637A (en) | Use of benzoate-containing compositions for treating glycine encephalopathy |